Trevor Allred
Stock Analyst at Oppenheimer
(4.68)
# 171
Out of 5,130 analysts
15
Total ratings
86.67%
Success rate
39.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trevor Allred
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Initiates: Outperform | $75 | $23.60 | +217.80% | 1 | Jan 7, 2026 | |
| DSGN Design Therapeutics | Initiates: Outperform | $18 | $9.39 | +91.69% | 1 | Jan 7, 2026 | |
| TBPH Theravance Biopharma | Initiates: Outperform | $27 | $19.05 | +41.71% | 1 | Dec 3, 2025 | |
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $250 → $275 | $206.54 | +33.15% | 8 | Nov 7, 2025 | |
| MBX MBX Biosciences | Maintains: Outperform | $38 → $80 | $31.66 | +152.68% | 2 | Sep 23, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Outperform | $85 | $92.41 | -8.02% | 1 | Sep 9, 2025 | |
| INVA Innoviva | Initiates: Outperform | $35 | $19.58 | +78.75% | 1 | Aug 11, 2025 |
Legend Biotech
Jan 7, 2026
Initiates: Outperform
Price Target: $75
Current: $23.60
Upside: +217.80%
Design Therapeutics
Jan 7, 2026
Initiates: Outperform
Price Target: $18
Current: $9.39
Upside: +91.69%
Theravance Biopharma
Dec 3, 2025
Initiates: Outperform
Price Target: $27
Current: $19.05
Upside: +41.71%
Ligand Pharmaceuticals
Nov 7, 2025
Maintains: Outperform
Price Target: $250 → $275
Current: $206.54
Upside: +33.15%
MBX Biosciences
Sep 23, 2025
Maintains: Outperform
Price Target: $38 → $80
Current: $31.66
Upside: +152.68%
Palvella Therapeutics
Sep 9, 2025
Initiates: Outperform
Price Target: $85
Current: $92.41
Upside: -8.02%
Innoviva
Aug 11, 2025
Initiates: Outperform
Price Target: $35
Current: $19.58
Upside: +78.75%